CN108785656A - A kind of pharmaceutical preparation and preparation method thereof reducing cervical cancer pathogenesis risk - Google Patents
A kind of pharmaceutical preparation and preparation method thereof reducing cervical cancer pathogenesis risk Download PDFInfo
- Publication number
- CN108785656A CN108785656A CN201710932292.6A CN201710932292A CN108785656A CN 108785656 A CN108785656 A CN 108785656A CN 201710932292 A CN201710932292 A CN 201710932292A CN 108785656 A CN108785656 A CN 108785656A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical preparation
- preparation
- lactoglobulin
- acidification
- black raspberry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1722—Plasma globulins, lactoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
The invention discloses a kind of pharmaceutical preparation and preparation method thereof reducing cervical cancer pathogenesis risk, the pharmaceutical preparation is made of carbomer, Polycarbophil, black raspberry extract, acidification lactoglobulin, glycerine, edetate sodium, Phenoxyethanol, purified water and triethanolamine.HPV viruse is inhibited to infect normal cell using acidification lactoglobulin in pharmaceutical preparation of the present invention, joint black raspberry extract Scavenger of ROS accumulation inhibits cell carcinogenesis risk, achievees the purpose that reduce cervical cancer pathogenesis risk.
Description
Technical field
The invention belongs to pharmaceutical technology fields, and in particular to a kind of pharmaceutical preparation and its system reducing cervical cancer pathogenesis risk
Preparation Method.
Background technology
Cervical carcinoma (cervical carcinoma) is the common cancer of female reproductive system, be happened at portio vaginalis and
Cervical canal, in global gynecological tumor being only second to breast cancer occupies second.In developing country, cervical carcinoma then belongs to common multiple
Gynecological tumor.There are 500,000 cervical carcinoma new cases in the whole world every year, accounts for the 5% of all cancer new cases, wherein 80% comes from
Developing country.The cause of disease of cervical carcinoma is not yet clear at present, and massive epidemiology data and research are thought, infects human papilloma shape
Viral (human papilloma virus, HPV), especially high-risk HPV infection (HPV16, HPV18) be main hazard because
Element.But not all HPV infection person can develop into cervical carcinoma, it is also contemplated that other factors, such as sexual life disorder,
Malnutrition etc..Many research reports point out that cervical carcinoma is related with micronutrient in recent years, it is verified that with people is prevented
The nutrient of class malignant tumour effect includes vitamin C, vitamin E, former blue and white element, resveratrol etc., and in fact these have
There is good Hardy dwarfing.In cervical carcinoma generating process, in body the increase of activity keto concentration can cause DNA and egg
White damage, finally promotes canceration.Antioxidant can make active oxygen lose activity, and prevent oxidative damage, to reduce uterine neck
The probability of carcinogenesis achievees the purpose that prevent cervical carcinoma.
Human papilloma virus HPV infects the epithelial cell of human skin tissue and mucous membrane tissue using people as unique host,
It is particularly concentrated on the positions such as oral cavity, trick and men and women's genitals.Virus is that HPV infection host is necessary with being in direct contact for cell
Prerequisite is damaged when the physical organization on skin or mucous membrane surface layer protects, and histocyte is caused to be exposed to free maturation virus,
Virus just has an opportunity to invade by the Micro trauma of this epithelial cell and enters cell, this is typically considered viral lifecycle
Incipient stage, and prevent optimal state.Equally, it can also be discharged from cell after virus maturation, to infect newly
Cell, caused at oral cavity, trick and men and women's genitals more infect and lesion, finally result in the state of an illness expansion, deteriorate and
Last immune system can not be removed to form condyloma acuminatum, cervical erosion, chronic cervicitis even tumour, for cervical carcinoma
Diseased region controls the normal physiological function of cell tissue, and DNA and egg white injury caused by reducing active oxygen accumulation can reach
Prevent the incidence probability of cervical carcinoma.Currently, the drug that can effectively prevent HPV viruse infection in the world is MSD Corp. HPV4
Valence vaccineWith the bivalent vaccine of GlaxoSmithKline PLC company", mainly still
The vaccine of prevention type, clinic confirm the vaccine of HPV almost can 100% ground prevent the infection of some HPV viruse strains, but it is not
It can prevent the infection of all types Strain, but domestic people limitation is only applicable to 9-25 Sui, and it is at high price.And it is controlling
Due to the immunoregulation medicament for not having specific drug thus to use in treatment, since generally existing can not effectively prevent HPV infection, treatment
It imitates indefinite, expensive etc. defect and greatly limits its use clinically, especially in the hair of low income
It is national in exhibition.
Invention content
Present invention aim to address existing pharmaceutical preparations can not effectively prevent Subclinical papillomavirus infection infection, curative effect not
Clear, expensive disadvantage provides a kind of pharmaceutical preparation and preparation method thereof blocking the human papilloma virus routes of infection, this
Using acidification lactoglobulin control HPV viruse infection normal cell while to combine black raspberry extract clear in invention pharmaceutical preparation
Except active oxygen is accumulated, inhibit cancerous tumor cell growth, achievees the purpose that prevent cervical carcinoma.
According to the first aspect of the invention, the present invention provides a kind of drugs blocking the human papilloma virus routes of infection
The pH of preparation, the pharmaceutical preparation is 4.5-6.5, and the pharmaceutical preparation is made of drug solution and pH adjusting agent；The pH tune
Section agent is triethanolamine；The drug solution by carbomer, Polycarbophil, black raspberry extract, acidification lactoglobulin, glycerine,
Edetate sodium, Phenoxyethanol and purified water composition.
Lactoglobulin is acidified described in pharmaceutical preparation of the present invention to be replaced with recombinant human serum albumin；The black raspberry extract
It is replaced with mulberries extract；The carbomer and Polycarbophil are replaced with carboxylic propyl methocel.
Preferably, the drug solution consists of the following compositions count by weight percentage：
Carbomer 1%wt-3%wt, Polycarbophil 1%wt-3%wt, black raspberry extract 1%wt-10%wt, glycerine
1%wt-3%wt, edetate sodium 0.05%wt-0.1%wt, Phenoxyethanol 0.5%wt-1%wt, surplus are purified water and acidification
Lactoglobulin, a concentration of 100-600 μ g/ml of the acidification lactoglobulin in drug solution.
Preferably, the acidification lactoglobulin is prepared by following methods：
It uses phosphate buffer to dissolve lactoglobulin 20g first, 3- hydroxy-phthalic anhydride solution 20g is added, stir
Mix 2-4 hours to obtain mixed liquor；
Then G25 desalting columns are used, desalting processing is carried out to mixed liquor using phosphate buffer solution as mobile phase；It receives
Ji Mubiaodanbaifeng can must be acidified lactoglobulin using aseptic filtration is concentrated by ultrafiltration.
It is acidified lactoglobulin to modify by acid anhydrides, wherein basic amino acids lysine, arginine are modified, and keep albumen whole
Iso-electric point declines, and presents acid.The protein amino acid sequence N-terminal of acidification carries positive charge and human papilloma virus HPV L1C
Negative electricity region is held to combine, to block human papilloma virus HPV to enter cell, the virus being combined can be arranged with gel rubber system
Except external.
Preferably, the black raspberry extract is prepared by following methods：
1) using fresh black raspberry fruit as raw material, impurity removing and soaking and washing are gone；
2) it cools to -20 DEG C to smash fruit, 18-24h is lyophilized in freeze drier, and outlet crushes；
3) it uses ethanol water (60%v) to dissolve to extract at 0-10 DEG C, filter-cloth filtering, low-temperature reduced-pressure distillation, is dried at concentration
Black raspberry extract is kept in dark place to obtain in sealing after dry.
The common extracting mode of black raspberry extract is because temperature and illumination are higher to activity influence, in order to solve the above problem originally
Invention can be very good the activity for retaining substance using the method for cryogenic freezing extraction.
Contain abundant anti-oxidation active substance, such as anthocyanidin, Huang in black raspberry (Black raspberry) extract
Keto-alcohol, resveratrol, ellagitannin and tannic acid.Detection finds that Antioxidants are several times as much as common kind and contain in black raspberry
Amount.Its stronger antioxygenic property and immunocyte regulatory function can understand the active oxygen accumulation of vaginal epithelial cell, reduce
The canceration of cell DNA and protein expression.Simultaneously experiments have shown that the growth of tumour cell can also be inhibited under a certain concentration dosage,
Achieve the effect that prevention and treatment.
According to another aspect of the present invention, the present invention provides a kind of drugs blocking the human papilloma virus routes of infection
The preparation method of preparation, includes the following steps：
1) carbomer, Polycarbophil is water-swellable rear for use using purifying；
2) the aqueous dissolution black raspberry extract of glycerine and purified water composition, acidification lactoglobulin and edetate sodium, are stirred
Mix uniform mixed liquor；
3) mixing in proportion at normal temperatures by step 1) and step 2) acquired solution, is then added Phenoxyethanol and stirs evenly
Obtain drug solution；
4) it adjusts drug solution pH=4.5-6.5 using triethanolamine and obtains pharmaceutical preparation.
The preparation of the present invention for reducing cervical cancer pathogenesis risk can be prepared into gel preparation, cream preparation；Preferably
Gel preparation is particularly suitable for vagina external-use gel, forms effective dose concentration in intravaginal mucous membrane, directly acts on vagina
Mucosa cells prevent HPV viruse infection and diffusion, remove the cell of the active oxygen accumulation of tissue, inhibit cervical cancer cell growth,
Have the function that prevent cervical carcinoma, external application advantage is that topical substance concentration is significantly better than oral and injection, to cell carcinogenesis reality
The effect now prevented and treated.
Reduction cervical cancer pathogenesis risk preparation of the present invention, can be used for preventing and/or treat women cervical carcinoma.
Mechanism of the present invention is：1) in the first stage of poisoning intrusion target cell, a large amount of positive electricity of protein surface band of acidification
Lotus is combined with the ends human papilloma virus HPV L1C negative electricity region, to block human papilloma virus HPV to enter cell, is combined
Virus be excluded in vitro with gel rubber system；2) contain abundant anti-oxidation active substance in black raspberry extract, such as spend
Green element, VC, VE etc. can be very good the activity for retaining antioxidant by the method for freezing extraction, pass through external-use gel shape
Formula is partially formed effective dose concentration in vagina, directly acts on the histocyte of active oxygen accumulation, balances free oxygen accumulation
Caused abnormal cell growth environment, reduces cell carcinogenesis risk, and the complicated polysaccharide component in black raspberry can form blocking disease
The glycoprotein of malicious particle infection cell is bonded channel, reduces infection of the virus to normal cell.External application advantage is gel rubber system
Excellent absorption viscosity can form the effect of topically effective substance high concentration, better than oral.
The pharmaceutical preparation that the present invention reduces cervical cancer pathogenesis risk has blocking HPV viruse invasion cell, prevents active oxygen
Significant advantages, the clinic such as normal cell function, safe without toxic side effect, of low cost is kept to be easy to push away DNA Damage
Extensively.
Specific implementation mode
In order to make the objectives, technical solutions and advantages of the present invention clearer, With reference to embodiment, to this
Invention is further described.It should be understood that these descriptions are merely illustrative, and it is not intended to limit the scope of the present invention.
Embodiment 1
It is as follows to be acidified lactoglobulin method：The PBS buffer solution of pH8.4 dissolves lactoglobulin 20g with 50 times of volumes, and 3- is added
Hydroxy-phthalic anhydride solution 20g is stirred 2-4 hours, using G25 desalting columns, using PBS as mobile phase, collects albumen
Peak, it is rear using aseptic filtration is concentrated by ultrafiltration, it can must be acidified lactoglobulin.
Black raspberry method for preparing extractive is as follows：Using fresh black raspberry fruit as raw material, impurity removing and soaking and washing are gone；
- 30 DEG C are cooled to smash fruit, 18-24h is lyophilized in freeze drier, and outlet is crushed to be dissolved using ethanol water (60%v),
It is extracted at 0-10 DEG C, filter-cloth filtering, seals and be kept in dark place after the drying of low-temperature reduced-pressure distillation and concentration.
The preparation method for blocking the pharmaceutical preparation of the human papilloma virus routes of infection, comprises the steps of：
1) carbomer and Polycarbophil is water-swellable rear for use using purifying；
2) the aqueous dissolution black raspberry extract and acidification lactoglobulin, edetate sodium of glycerine and purified water composition, is stirred
Mix uniform mixed liquor；
3) mixing in proportion at normal temperatures by step 1) and step 2) acquired solution, is then added Phenoxyethanol and stirs evenly
Obtain drug solution；
4) it adjusts drug solution pH=4.5-6.5 using triethanolamine and obtains pharmaceutical preparation；
The weight percent of each substance is as follows in the drug solution：
The pharmaceutical preparation of above-mentioned preparation is prepared into gel preparation：Gel is filled to gynaecology's dress with injecting in pipe, and nitrogen is protected
Lower sealing is protected, the preparation of external preparation is completed.
Embodiment 2
The preparation method is the same as that of Example 1 for acidification lactoglobulin and black raspberry extract, and difference lies in each objects in drug solution
The weight percent of matter, the weight percent of each substance is as follows in the present embodiment drug solution：
Gel is filled to gynaecology's dress with injecting in pipe, nitrogen protection lower sealing completes the preparation of external preparation.
Embodiment 3
The effect of in order to further prove gel of the present invention, applicant carried out following clinical test verifications.
Suffered from for treating the positive repeated infection of HPV viruse infection using the gel (embodiment 1 or 2 prepares gained) of the present invention
Person has done preliminary on probation observation, the results showed that, the gel for treating HPV viruse positive treatment is effective, no any stimulation and bad anti-
It answers.
High-risk HPV16,18 the infected 5 are turned out cloudy, specifically using positive-virus after anti-HPV viruse gel dressing 3 months
The results are shown in Table 1, higher than document report (《Microbes&Infection》,2016,18(2):148, A randomized open-
label clinical trial of an anti-HPV biological dressing(JB01-BD)administered
Intravaginally to treat high-risk HPV infection) acid anhydrides modify lactoglobulin dressing to high-risk HPV
Viral negative conversion rate 60.5%.Block HPV viruse particle infection during, acidification lactoglobulin can with after viral adsorption particle with
Exclude it is internal, polysaccharide structures in black raspberry extract can with the glycoprotein binding site on closing cell surface, blocking virus into
Enter intracellular channel.Also there is certain suppression to mutant simultaneously with oxygen radical in the ingredients such as anthocyanidin in black raspberry extract
It makes and uses.
Gel is prepared using the present invention, case selection is HPV high-risk virals positive patient 5, validity period 3 months, PCR inspections
Survey HPV viruse E6, E7mRNA.
Table 1 tests case treatment restrovirus detection variation
| Serial number | Gender | Age | Progress note for the first time | Progress note again | Medication cycle |
| 1 | Female | 37 | HPV-18 is positive | HPV-18 is negative | 25,3 months |
| 2 | Female | 37 | HPV-16 is positive | HPV-16 is negative | 25,3 months |
| 3 | Female | 38 | HPV-16 is positive | HPV-16 is negative | 25,3 months |
| 4 | Female | 42 | HPV-18 is positive | HPV-18 is negative | 25,3 months |
| 5 | Female | 35 | HPV-16 is positive | HPV-16 is negative | 25,3 months |
Although embodiments of the present invention are described in detail, it should be understood that, without departing from the present invention's
In the case of spirit and scope, can embodiments of the present invention be made with various changes, replacement and change.
Claims (10)
1. a kind of pharmaceutical preparation, it is characterised in that：The pH of the pharmaceutical preparation is 4.5-6.5, and the pharmaceutical preparation is molten by drug
Liquid and pH adjusting agent composition；The pH adjusting agent is triethanolamine；The drug solution is by carbomer, Polycarbophil, black raspberry
Extract, acidification lactoglobulin, glycerine, edetate sodium, Phenoxyethanol and purified water composition.
2. pharmaceutical preparation according to claim 1, it is characterised in that：The drug solution count by weight percentage by with
It is lower at being grouped as：
Carbomer 1%wt-3%wt, Polycarbophil 1%wt-3%wt, black raspberry extract 1%wt-10%wt, glycerine 1%wt-
3%wt, edetate sodium 0.05%wt-0.1%wt, Phenoxyethanol 0.5%wt-1%wt, surplus are purified water and acidification milk-globule egg
In vain, a concentration of 100-600 μ g/ml of the acidification lactoglobulin in drug solution.
3. pharmaceutical preparation according to claim 1, it is characterised in that：The acidification lactoglobulin is prepared by following methods：
It uses phosphate buffer to dissolve lactoglobulin first, 3- hydroxy-phthalic anhydride solution is added, stir 2-4 hours
Obtain mixed liquor；
Then G25 desalting columns are used, desalting processing is carried out to mixed liquor using phosphate buffer solution as mobile phase；Collect breast
Globulin peak can must be acidified lactoglobulin using aseptic filtration is concentrated by ultrafiltration.
4. pharmaceutical preparation according to claim 1, it is characterised in that：The black raspberry extract is prepared by following methods：
1) using fresh black raspberry fruit as raw material, impurity removing and soaking and washing are gone；
2) fruit is smashed in cooling, and freeze drier freeze-drying, outlet crushes；
3) it is dissolved using ethanol water, is extracted at 0-10 DEG C, after filter-cloth filtering, low-temperature reduced-pressure distillation and concentration, after drying
Black raspberry extract is kept in dark place to obtain in sealing.
5. a kind of dosage form of any one of claim 1-4 pharmaceutical preparations, it is characterised in that：The dosage form of the pharmaceutical preparation is
Gel preparation or cream preparation.
6. the dosage form of pharmaceutical preparation described in a kind of claim 5, it is characterised in that：The dosage form of the pharmaceutical preparation is gel system
Agent.
7. the dosage form of pharmaceutical preparation described in a kind of claim 6, it is characterised in that：The dosage form of the pharmaceutical preparation is vagina external application
Gel preparation.
8. a kind of claim 1-4 any one of them pharmaceutical preparations, it is characterised in that：The acidification lactoglobulin recombined human
Blood albumin replaces；The black raspberry extract is replaced with mulberries extract；The carbomer and Polycarbophil carboxylic propyl first
Base cellulose replaces.
9. a kind of preparation method of any one of claim 1-4 pharmaceutical preparations, includes the following steps：
1) carbomer, Polycarbophil is water-swellable rear for use using purifying；
2) the aqueous dissolution black raspberry extract of glycerine and purified water composition, acidification lactoglobulin and edetate sodium, stirring are equal
It is even to obtain mixed liquor；
3) mixing in proportion at normal temperatures by step 1) and step 2) acquired solution, is then added Phenoxyethanol and stirs evenly to obtain medicine
Object solution；
4) it adjusts drug solution pH=4.5-6.5 using triethanolamine and obtains pharmaceutical preparation.
10. a kind of purposes of any one of claim 1-4 pharmaceutical preparations, it is characterised in that：It is prepared by the pharmaceutical preparation
Reduce the application in women cervical cancer pathogenesis risk drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710932292.6A CN108785656A (en) | 2017-10-10 | 2017-10-10 | A kind of pharmaceutical preparation and preparation method thereof reducing cervical cancer pathogenesis risk |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710932292.6A CN108785656A (en) | 2017-10-10 | 2017-10-10 | A kind of pharmaceutical preparation and preparation method thereof reducing cervical cancer pathogenesis risk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108785656A true CN108785656A (en) | 2018-11-13 |
Family
ID=64094556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710932292.6A Pending CN108785656A (en) | 2017-10-10 | 2017-10-10 | A kind of pharmaceutical preparation and preparation method thereof reducing cervical cancer pathogenesis risk |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108785656A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113171445A (en) * | 2021-04-30 | 2021-07-27 | 海南众康悦医疗器械有限公司 | Modified beta-lactoglobulin and biological preparation for preventing and treating HPV (human papillomavirus) virus infection |
| CN115581762A (en) * | 2022-10-31 | 2023-01-10 | 湖南中禧医疗科技有限公司 | Medical bioprotein repair gel for clearing HPV virus infection and preparation method thereof |
| CN116421705A (en) * | 2023-02-27 | 2023-07-14 | 迈迪速能医学技术（天津）有限公司 | Pharmaceutical preparation for reducing cervical cancer incidence risk |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102631666A (en) * | 2012-03-14 | 2012-08-15 | 杨霞 | Preparation method for biological agent for preventing and controlling human papilloma virus infection |
| CN102908611A (en) * | 2012-10-26 | 2013-02-06 | 太原锦波生物医药科技有限公司 | Bioprotein dressing and bioprotein invisible film for preventing and controlling human papilloma virus infection |
| CN104758615A (en) * | 2015-04-15 | 2015-07-08 | 胡运冲 | Traditional Chinese medicinal composition for treating cervical cancer with syndromes of damp-heat and amassing poison |
-
2017
- 2017-10-10 CN CN201710932292.6A patent/CN108785656A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102631666A (en) * | 2012-03-14 | 2012-08-15 | 杨霞 | Preparation method for biological agent for preventing and controlling human papilloma virus infection |
| CN102908611A (en) * | 2012-10-26 | 2013-02-06 | 太原锦波生物医药科技有限公司 | Bioprotein dressing and bioprotein invisible film for preventing and controlling human papilloma virus infection |
| CN104758615A (en) * | 2015-04-15 | 2015-07-08 | 胡运冲 | Traditional Chinese medicinal composition for treating cervical cancer with syndromes of damp-heat and amassing poison |
Non-Patent Citations (3)
| Title |
|---|
| XUETAO GUO等: "A randomized open-label clinical trial of an anti-HPV biological dressing (JB01-BD) administered intravaginally to treat high-risk HPV infection", 《MICROBES AND INFECTION》 * |
| ZHAOXIA ZHANG等: "A black raspberry extract inhibits proliferation and regulates apoptosis in cervical cancer cells", 《GYNECOLOGIC ONCOLOGY》 * |
| 李珉珉: "酸酐修饰人血清白蛋白的抗病毒活性及安全性研究", 《中国博士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113171445A (en) * | 2021-04-30 | 2021-07-27 | 海南众康悦医疗器械有限公司 | Modified beta-lactoglobulin and biological preparation for preventing and treating HPV (human papillomavirus) virus infection |
| CN115581762A (en) * | 2022-10-31 | 2023-01-10 | 湖南中禧医疗科技有限公司 | Medical bioprotein repair gel for clearing HPV virus infection and preparation method thereof |
| CN116421705A (en) * | 2023-02-27 | 2023-07-14 | 迈迪速能医学技术（天津）有限公司 | Pharmaceutical preparation for reducing cervical cancer incidence risk |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101328219B (en) | Nano liposome anti-HPV, gynecological inflammation pathogen specific compound IgY and combined preparation thereof | |
| CN101422585B (en) | Pharmaceutical use of medicine composition containing zedoary turmeric oil | |
| CN108785656A (en) | A kind of pharmaceutical preparation and preparation method thereof reducing cervical cancer pathogenesis risk | |
| JP2002526452A (en) | Oleander extract, its pharmaceutical composition and its preparation method | |
| CN104353058B (en) | Pokeweed antiviral protein lyophilized powder complexing agent and preparation method thereof | |
| CN111012896A (en) | Functional dressing for preventing and controlling human papilloma virus infection and preparation method thereof | |
| JP6661800B2 (en) | Alginate sulfate and its use in the manufacture of drugs and health foods for the prevention and treatment of human papillomavirus disease | |
| CN106177911A (en) | A kind of biological composition dressing of prophylactic treatment HPV infection | |
| CN104491838B (en) | Anti-HPV (human papillomavirus) gel dressing and preparation method thereof | |
| CN109966434B (en) | Traditional Chinese medicine composition, traditional Chinese medicine compound preparation, and preparation method and application thereof | |
| CN102652778A (en) | Medicinal composition | |
| JP4854742B2 (en) | Use of Nocardia rubra cell wall skeleton in the preparation of anti-HPV infection drugs | |
| CN109602904A (en) | A kind of immune globulin IgY plural gel agent for gynaecological imflammation | |
| CN109276703A (en) | Antiviral protein of plant complexing agent and preparation method thereof | |
| CN114903944B (en) | Composition and preparation for improving cervical HPV infection symptoms and preparation method | |
| US20040109899A1 (en) | Antiviral medicament and method for producing and using the same for the prophylactic and therapeutic treatment of papillomavirus induced tumors, lesions and deseases | |
| CN114886996B (en) | Skin-care oil solution for treating cervicitis through vagina, and preparation method and application thereof | |
| CN116606371A (en) | IgY (IgY) for preventing and treating condyloma acuminatum 16-valent HPV (human papilloma Virus) composite yolk neutralizing antibody as well as preparation and application thereof | |
| CN106563121B (en) | BFGF bovine basic fibroblast growth factor gel is repairing the application in acne rosacea skin lesion | |
| CN110292621A (en) | The antitoxin antibacterial complexing agent of anti-HPV viruse infection and its preparation method of phase inversion gel | |
| CN106177900A (en) | A kind of gel of anti-human papilloma virus (anti-HPV) and preparation method thereof | |
| CN106177007A (en) | A kind of Chinese medicine suppository of cervical disease for treating high-risk HPV persistent infection and preparation method thereof | |
| CN112409478A (en) | Broad-spectrum HPV antibody and preparation method and application thereof | |
| CN112587632A (en) | Biological preparation for preventing and treating HPV (human papillomavirus) infection and preparation method thereof | |
| CN111568937A (en) | Application of pien Tze Huang and preparation thereof in preparation of medicine for promoting healing of refractory wound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181113 |